Defence Therapeutics Inc (OP: DTCFF )

0.5664 -0.0943 (-14.27%)

Streaming Delayed Price Updated: 2:13 PM EDT, Jul 29, 2024 Add to My Watchlist

Price and Volume

Volume	300
Open	0.5664
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.6607
Today's Range	0.5664 - 0.5664
52wk Range	0.5723 - 2.500
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

November 14, 2023

(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in

Via PressReach

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Performance

YTD	-65.46%	-65.46%
1 Month	-12.86%	-12.86%
3 Month	-35.49%	-35.49%
6 Month	-64.49%	-64.49%
1 Year	-73.16%	-73.16%

More News

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

November 07, 2023

Via PressReach

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

Via FinancialNewsMedia

Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer

October 18, 2023

Via PressReach

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Via PressReach

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Via PressReach

Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science

October 10, 2023

Via PressReach

Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

September 26, 2023

Via PressReach

BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment

May 10, 2023

Via Newsfile

BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News

May 04, 2023

Via Newsfile

Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

September 29, 2022

Via Newsfile

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

September 21, 2022

Via Newsfile

Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative

September 16, 2022

Via Newsfile

Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)

October 19, 2021

Via AB Newswire

Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)

October 12, 2021

Via AB Newswire

Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)

October 05, 2021

Via AB Newswire

Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)

September 28, 2021

Via AB Newswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.